- Home
- ZYME vs NBXG Comparison
ZYME vs NBXG Comparison
Compare ZYME & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- NBXG
- Stock Information
- Founded
- ZYME 2003
- NBXG 2021
- Country
- ZYME United States
- NBXG United States
- Employees
- ZYME N/A
- NBXG N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- NBXG Trusts Except Educational Religious and Charitable
- Sector
- ZYME Health Care
- NBXG Finance
- Exchange
- ZYME Nasdaq
- NBXG Nasdaq
- Market Cap
- ZYME 983.6M
- NBXG 1.1B
- IPO Year
- ZYME 2017
- NBXG N/A
- Fundamental
- Price
- ZYME $14.39
- NBXG $13.46
- Analyst Decision
- ZYME Buy
- NBXG
- Analyst Count
- ZYME 6
- NBXG 0
- Target Price
- ZYME $19.17
- NBXG N/A
- AVG Volume (30 Days)
- ZYME 340.7K
- NBXG 243.7K
- Earning Date
- ZYME 03-05-2025
- NBXG 01-01-0001
- Dividend Yield
- ZYME N/A
- NBXG 10.25%
- EPS Growth
- ZYME N/A
- NBXG N/A
- EPS
- ZYME N/A
- NBXG N/A
- Revenue
- ZYME $62,199,000.00
- NBXG N/A
- Revenue This Year
- ZYME $21.53
- NBXG N/A
- Revenue Next Year
- ZYME N/A
- NBXG N/A
- P/E Ratio
- ZYME N/A
- NBXG N/A
- Revenue Growth
- ZYME N/A
- NBXG N/A
- 52 Week Low
- ZYME $7.97
- NBXG $9.31
- 52 Week High
- ZYME $17.70
- NBXG $12.23
- Technical
- Relative Strength Index (RSI)
- ZYME 49.88
- NBXG 48.83
- Support Level
- ZYME $14.45
- NBXG $13.51
- Resistance Level
- ZYME $15.25
- NBXG $13.86
- Average True Range (ATR)
- ZYME 0.73
- NBXG 0.16
- MACD
- ZYME -0.02
- NBXG -0.02
- Stochastic Oscillator
- ZYME 64.58
- NBXG 47.99
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".